Mental Process
Newleos Therapeutics Launches with $93.5M to Advance Novel Neuropsychiatric Treatments
Newleos Therapeutics, mental health, neuropsychiatry, Roche assets, Series A funding, anxiety disorders, substance use disorders, GABA modulators
Pharma Ads Make Waves at Super Bowl 2025: Pfizer Wins Hearts, Hims & Hers Drives Engagement
Super Bowl 2025, pharmaceutical advertising, Pfizer, Hims & Hers, ad likeability, viewer engagement, healthcare marketing, cancer awareness, weight loss drugs
AstraZeneca Shares Rise as China Investigation Impact Appears Limited
AstraZeneca, China investigation, share price, financial performance, import taxes, investor confidence
CDC Orders Retraction of Research Papers and Removes Website Content Amid New Language Restrictions
CDC, research retraction, website content removal, language restrictions, LGBTQ, gender identity, scientific publications
Biotech IPO Momentum: Maze and Metsera’s Dual Debut Signals Renewed Market Optimism
Biotech IPOs, Maze Therapeutics, Metsera, obesity treatment, precision medicine, market optimism, 2025 IPO trends
RFK Jr. Faces Intense Scrutiny in Senate Confirmation Hearings for HHS Secretary
Robert F. Kennedy Jr., Senate confirmation hearings, Health and Human Services Secretary, Trump nominee, vaccine stance, Republican doubts
Breaking the Silence: Endo’s “I Got Somebody” Campaign Encourages Men to Seek Help for Peyronie’s Disease
Peyronie’s disease, men’s health, Endo, “I Got Somebody” campaign, urology specialists, nonsurgical treatment options, disease awareness, stigma reduction.
Retro Biosciences, Backed by Sam Altman, Seeks $1 Billion to Extend Human Lifespan by 10 Years
Retro Biosciences, Sam Altman, Human Lifespan Extension, Biotechnology, Series A Funding, Artificial Intelligence in Healthcare
FDA Delays Decision on Stealth BioTherapeutics’ Elamipretide for Barth Syndrome Until April 2025
Barth Syndrome, Elamipretide, FDA Decision, Stealth BioTherapeutics, Drug Approval Delay
Biotech IPO Market Expected to Rebound in 2025 with Increased Investor Optimism
Biotech IPOs, 2025 Outlook, Investor Optimism, Therapeutic Innovation, Strategic Differentiation